Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 7 | 2022 | 399 | 0.990 |
Why?
|
| Liver Neoplasms | 7 | 2022 | 755 | 0.850 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2022 | 952 | 0.590 |
Why?
|
| RNA Helicases | 1 | 2014 | 35 | 0.450 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 123 | 0.440 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 64 | 0.440 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2012 | 26 | 0.410 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 269 | 0.400 |
Why?
|
| Eye | 1 | 2012 | 111 | 0.390 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 105 | 0.390 |
Why?
|
| Cell Survival | 1 | 2014 | 983 | 0.380 |
Why?
|
| Anoikis | 1 | 2010 | 8 | 0.350 |
Why?
|
| Ceramides | 1 | 2010 | 35 | 0.350 |
Why?
|
| Protein Phosphatase 2 | 1 | 2010 | 17 | 0.350 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 413 | 0.330 |
Why?
|
| alpha-Fetoproteins | 4 | 2022 | 44 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 3 | 2018 | 1396 | 0.280 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2019 | 151 | 0.280 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 2331 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 1131 | 0.160 |
Why?
|
| Membrane Proteins | 2 | 2018 | 1227 | 0.160 |
Why?
|
| Bile Duct Neoplasms | 1 | 2018 | 95 | 0.140 |
Why?
|
| Taxoids | 1 | 2017 | 124 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 203 | 0.140 |
Why?
|
| Hypertension | 1 | 2022 | 747 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 2506 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 293 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2018 | 434 | 0.120 |
Why?
|
| DEAD Box Protein 58 | 1 | 2014 | 11 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 366 | 0.110 |
Why?
|
| Mice | 4 | 2018 | 11851 | 0.100 |
Why?
|
| Pericytes | 1 | 2012 | 13 | 0.100 |
Why?
|
| Interferon Type I | 1 | 2014 | 186 | 0.100 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2012 | 9 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 31 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1545 | 0.100 |
Why?
|
| RNA Polymerase II | 1 | 2012 | 57 | 0.100 |
Why?
|
| Humans | 15 | 2022 | 89961 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 1048 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 1185 | 0.100 |
Why?
|
| Membrane Microdomains | 1 | 2011 | 54 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2014 | 268 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2022 | 171 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2011 | 126 | 0.090 |
Why?
|
| Lysine | 1 | 2011 | 152 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 182 | 0.090 |
Why?
|
| Holoenzymes | 1 | 2010 | 10 | 0.090 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2010 | 6 | 0.090 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 389 | 0.090 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 86 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2026 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 198 | 0.080 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 338 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2014 | 2016 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2010 | 426 | 0.080 |
Why?
|
| HeLa Cells | 1 | 2010 | 515 | 0.080 |
Why?
|
| Cytoskeleton | 1 | 2010 | 195 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 1576 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 2370 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2010 | 281 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2011 | 677 | 0.080 |
Why?
|
| Prognosis | 3 | 2022 | 3798 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 290 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 784 | 0.070 |
Why?
|
| Cell Line | 1 | 2012 | 2495 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1158 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2010 | 1130 | 0.070 |
Why?
|
| Animals | 4 | 2018 | 27528 | 0.070 |
Why?
|
| Apoptosis | 1 | 2014 | 1718 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2021 | 8273 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2021 | 1497 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3252 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2012 | 3404 | 0.060 |
Why?
|
| Aged | 5 | 2020 | 19254 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2017 | 1714 | 0.050 |
Why?
|
| Middle Aged | 5 | 2020 | 26146 | 0.050 |
Why?
|
| Europe | 1 | 2022 | 324 | 0.050 |
Why?
|
| Male | 5 | 2020 | 42674 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2018 | 20 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 841 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 726 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2017 | 88 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2017 | 79 | 0.040 |
Why?
|
| Internationality | 1 | 2017 | 70 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 263 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 332 | 0.030 |
Why?
|
| Homeostasis | 1 | 2018 | 418 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 288 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 1778 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 569 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1929 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1284 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 855 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 848 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1169 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2017 | 499 | 0.030 |
Why?
|
| Female | 4 | 2019 | 46587 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 376 | 0.030 |
Why?
|
| Adult | 3 | 2018 | 26816 | 0.030 |
Why?
|
| Mutation | 2 | 2017 | 4168 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 1670 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 2000 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 139 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2011 | 73 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 303 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 223 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2011 | 121 | 0.020 |
Why?
|
| Endocytosis | 1 | 2011 | 180 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 283 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 173 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 793 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2327 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 885 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2011 | 759 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1491 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6783 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2887 | 0.020 |
Why?
|
| Kidney | 1 | 2011 | 1148 | 0.020 |
Why?
|